Lv4
620 积分 2021-05-07 加入
Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study
1个月前
已完结
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
1年前
已完结
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
2年前
已完结
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
2年前
已完结
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa
2年前
已完结
皖公网安备34019202002308
